Combining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer models

Summary: Second mitochondrial activator of caspase (SMAC) mimetics (SMACm) and bromodomain and extra-terminal domain (BET) inhibitors (BETi) are two distinct classes of novel anticancer therapeutics. So far, broad clinical benefit for either monotherapy has not been achieved, calling for effective c...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ksenija Slavic Obradovic, Florian Ebner, Artem V. Artemov, Martina Miotto, Paula-Elena Traexler, Robin Jacob, Ha Pham Thi Thanh, Regina Ruzicka, Andreas Wernitznig, Ines Baumann, Daniel Gerlach, Maria-Antonietta Impagnatiello, Salvatore Siena, Mary Murphy, Reniqua House, Ulrich Reiser, Valeria Santoro, Johannes Popow, Sebastian Carotta, Anke Baum, Jesse Lipp, Alberto Bardelli, Ulrike Tontsch-Grunt, Mariangela Russo, Martin Aichinger
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-09-01
coleção:	Cell Reports Medicine
Assuntos:	SMAC mimetic cIAP BET inhibition cell death tumor microenvironment combination therapy
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2666379125003866
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!